Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Faster Aspart in Children, Adolescents and Adults with T1D
NCT03407599Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2018
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of faster-acting insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin aspart concentration-time curve from 0 to 12 hours. Started Jan 2018; status: completed.
02
Drugs
faster-acting insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03407599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407599.